Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 1/2001

01-07-2001 | Original Article

Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial

Authors: Primo N. Lara, David R. Gandara, Jeff Longmate, Paul H. Gumerlock, Derick H. Lau, Martin J. Edelman, Regina Gandour-Edwards, Philip C. Mack, Valerie Israel, James Raschko, Paul Frankel, Edith A. Perez, Heinz Lenz, James H. Doroshow

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2001

Login to get access
Metadata
Title
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial
Authors
Primo N. Lara
David R. Gandara
Jeff Longmate
Paul H. Gumerlock
Derick H. Lau
Martin J. Edelman
Regina Gandour-Edwards
Philip C. Mack
Valerie Israel
James Raschko
Paul Frankel
Edith A. Perez
Heinz Lenz
James H. Doroshow
Publication date
01-07-2001
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2001
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800100293

Other articles of this Issue 1/2001

Cancer Chemotherapy and Pharmacology 1/2001 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine